Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 06, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
Currently Reading
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
June 05, 2017
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 04, 2017
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Do We Have Adequate Surveillance in Cancer Survivor Care?
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
June 01, 2017
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges

Surabhi Dangi-Garimella, PhD
At the 2017 American Society of Clinical Oncology Annual Meeting, oncologists heard from fellow experts on the best way to navigate this daunting payment reform challenge.
Whether or not oncologists want to, CMS’ new payment model, the Medicare Access and CHIP Reauthorization Act (MACRA), is now live. MACRA replaced the Sustainable Growth Rate formula through the Quality Payment Program (QPP), which includes 2 tracks: Merit-based Incentive Payment System (MIPS) and Advanced Alternative Payment Models (APMs). At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, oncologists heard from fellow experts on the best way to navigate this daunting payment reform challenge.

The learning objectives of the session included the practice impact of MACRA, quality reporting and/or APM options under MACRA, and the impact of APMs on the Medicare.

Blase N. Polite, MD, MPP, associate professor of medicine, The University of Chicago, explained the 2 choices that practices have under QPP: MIPS and APMs. “There are no fully blessed oncology payment models yet, unless you choose the 2-sided risk model offered under the Oncology Care Model (OCM),” Polite said. This provided impetus for ASCO to develop its own APM, he explained.

In 2017, which is the first performance period, MIPS incorporates scores for quality, advancing care information (ACI), and improvement activities (IA), Polite said. “Cost, unfortunately, was not included in the 2017 MIPS program score,” Polite said, but will find a place in the 2018 scores.

Payment, he explained, will be based on where a practice falls along the range of low to high performers, compared with the National Median Composite Score. The 2019 scores are based on 2017 performance. A significant chunk (60%) of the score is driven by quality reporting, formerly known as the Physician Quality Reporting Score.

While the general oncology measures set includes 19 reportable measures that are a mix of process and outcome measures, reporting requirements mandate only 6 measures, at least 1 of which should be a outcome/high-priority measure, Polite said. Further, the practice is expected to report on at least 50% of patients eligible for each measure in 2017, which includes both Medicare and commercially insured patients.



 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!